Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms EYLEA-PMS
- Sponsors Bayer
- 30 Aug 2019 Planned End Date changed from 31 Aug 2020 to 31 Oct 2020.
- 30 Aug 2019 Planned primary completion date changed from 30 Jun 2020 to 30 Sep 2020.
- 06 Mar 2019 Status changed from not yet recruiting to recruiting.